Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) shares gapped up prior to trading on Wednesday . The stock had previously closed at $17.96, but opened at $18.57. Beta Bionics shares last traded at $18.61, with a volume of 43,897 shares.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on BBNX. Robert W. Baird initiated coverage on Beta Bionics in a research report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price target on the stock. The Goldman Sachs Group assumed coverage on Beta Bionics in a research note on Friday, May 30th. They issued a "neutral" rating and a $16.00 price target for the company. Leerink Partnrs upgraded shares of Beta Bionics to a "strong-buy" rating in a research note on Monday, February 24th. Stifel Nicolaus began coverage on Beta Bionics in a report on Monday, February 24th. They set a "buy" rating and a $25.00 price objective on the stock. Finally, Lake Street Capital started coverage on shares of Beta Bionics in a report on Monday, February 24th. They issued a "buy" rating and a $30.00 price target for the company. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Beta Bionics presently has an average rating of "Moderate Buy" and an average target price of $23.13.
Check Out Our Latest Stock Analysis on Beta Bionics
Beta Bionics Stock Down 2.4%
The stock's 50-day simple moving average is $13.05.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.01).
Insider Transactions at Beta Bionics
In other Beta Bionics news, CFO Stephen Feider sold 1,497 shares of the stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $17.89, for a total transaction of $26,781.33. Following the completion of the sale, the chief financial officer now directly owns 45,503 shares of the company's stock, valued at approximately $814,048.67. This represents a 3.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 4,519 shares of company stock valued at $80,845.
Hedge Funds Weigh In On Beta Bionics
A number of large investors have recently made changes to their positions in the business. Strs Ohio acquired a new stake in shares of Beta Bionics during the first quarter worth $29,000. Corebridge Financial Inc. acquired a new position in shares of Beta Bionics in the 1st quarter valued at $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Beta Bionics during the 1st quarter worth about $95,000. MetLife Investment Management LLC purchased a new position in shares of Beta Bionics during the 1st quarter valued at approximately $102,000. Finally, Deutsche Bank AG acquired a new stake in Beta Bionics in the 1st quarter worth about $148,000.
Beta Bionics Company Profile
(
Get Free Report)
Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Featured Stories
Before you consider Beta Bionics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.
While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
